<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667377</url>
  </required_header>
  <id_info>
    <org_study_id>1404-0036</org_study_id>
    <secondary_id>2020-002479-37</secondary_id>
    <nct_id>NCT04667377</nct_id>
  </id_info>
  <brief_title>A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight</brief_title>
  <official_title>A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with&#xD;
      body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot&#xD;
      participate. The purpose of this study is to find out whether a medicine called BI 456906&#xD;
      helps people lose weight.&#xD;
&#xD;
      Participants are put into 5 groups by chance. 4 groups get different doses of BI 456906. The&#xD;
      fifth group gets placebo. Participants get BI 456906 or placebo as injections under the skin&#xD;
      once a week. Placebo injections look like BI 456906 injections but do not contain any&#xD;
      medicine.&#xD;
&#xD;
      Participants are in the study for about a year. During this time, there are about 20&#xD;
      in-person visits to the study site. At the study site visits, doctors measure participants'&#xD;
      body weight. Results are compared between the BI 456906 groups and the placebo group. The&#xD;
      doctors also regularly check the general health of the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">October 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 29, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in body weight</measure>
    <time_frame>From baseline to week 46</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight loss of ≥ 5 percent (%) of baseline weight</measure>
    <time_frame>At week 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss of ≥ 10 percent (%) of baseline weight</measure>
    <time_frame>At week 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss of ≥ 15 percent (%) of baseline weight</measure>
    <time_frame>At week 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body weight (kg)</measure>
    <time_frame>From baseline to week 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in waist circumference (cm)</measure>
    <time_frame>From baseline to week 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in systolic blood pressure (mmHg)</measure>
    <time_frame>From baseline to week 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in diastolic blood pressure (mmHg)</measure>
    <time_frame>From baseline to week 46</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Very low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 456906</intervention_name>
    <description>BI 456906</description>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_label>Medium dose group</arm_group_label>
    <arm_group_label>Very low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult ≥ 18 years and &lt; 75 years of age at screening&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with ICH-GCP and local&#xD;
             legislation prior to admission to the trial.&#xD;
&#xD;
          -  Obesity or Overweight defined as BMI ≥27 kg/m2 at screening&#xD;
&#xD;
          -  A minimum absolute body weight of 70 kg for females and 80 kg for males at screening&#xD;
&#xD;
          -  Male or female participants. Women of childbearing potential (WOCBP)1 must be willing&#xD;
             and able to use two forms of effective contraception where at least one form is highly&#xD;
             effective methods of birth control per ICH M3 (R2) that result in a low failure rate&#xD;
             of less than 1% per year when used consistently and correctly. A list of contraception&#xD;
             methods meeting these criteria is provided in the patient information.&#xD;
&#xD;
          -  Patients must have undergone at least one previous unsuccessful nonsurgical&#xD;
             weight-loss attempt per investigator's judgement&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Body weight change of over +/- 5% or more in the past 12 weeks prior to randomization.&#xD;
             There must be documentation of weight in the past 12 weeks before randomization.&#xD;
&#xD;
          -  Obesity induced by an endocrinologic disorder (i.e. Cushing Syndrome, hypogonadism,&#xD;
             growh hormone deficiency. However, well controlled hypothyroidism, polycystic ovarian&#xD;
             disease are still allowed)&#xD;
&#xD;
          -  A HbA1c ≥ 6.5% at screening or diagnosed with type 1 or type 2 diabetes mellitus&#xD;
&#xD;
          -  Exposure to Glucagon like peptide-1 receptor agonist (GLP-1Ra) based therapies within&#xD;
             three months prior to screening&#xD;
&#xD;
          -  Any suicidal behaviour in the past 2 years, any suicidal ideation of type 4 or 5 in&#xD;
             the Columbia-Suicide Severity Rating Scale (CSSRS) within 3 months before screening,&#xD;
             or during screening period&#xD;
&#xD;
          -  History of major depressive disorder within 2 years before randomization&#xD;
&#xD;
          -  Major depressive symptoms (defined as a screening Patient Health Questionnaire-9&#xD;
             [PHQ-9] score ≥15) at screening and/or during screening period&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders at&#xD;
             screening&#xD;
&#xD;
          -  Chronic or relevant acute infections (including but not limited to respiratory tract&#xD;
             infections, urinary tract infection, bladder infection, enterocolitis, abscess,&#xD;
             tuberculosis, meningitis, influenza, Epstein-Barr virus, HIV/AIDS, and hepatitis B or&#xD;
             C, and severe acute respiratory syndrome coronavirus type 19 (SARS CoV-2) (as&#xD;
             confirmed by Polychain reaction (PCR) test)), within 2 weeks from screening or during&#xD;
             screening.&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boden Institute of Obesity, Nutrition, Exercies and Eating Disorders</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Vangoitsenhoven</last_name>
      <phone>+32 16 346994</phone>
      <email>roman.vangoitsenhoven@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bluewater Clinical Research</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John O'Mahony</last_name>
      <phone>519-344-6612</phone>
      <email>john@bwresearch.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital at Gangdong</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>PT &amp; R</name>
      <address>
        <city>Beek</city>
        <zip>6191 JW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivienne Van de Walle</last_name>
      <phone>+31 (0)850-604605</phone>
      <email>vivienne.vandewalle@ptr.nu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Newtown Wellington NZ</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metabolic Health Center</name>
      <address>
        <city>Poznan</city>
        <zip>60592</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pawel Bogdanski</last_name>
      <phone>48 502 760 006</phone>
      <email>pawelbogdanski73@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clifton Medical Centre, Rotherham</name>
      <address>
        <city>Rotherham</city>
        <zip>S65 1DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Capehorn</last_name>
      <phone>+44 0844 4773622</phone>
      <email>mcapehorn@yahoo.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

